Oral GLP-1 Pills Compared: Foundayo vs Wegovy Pill vs Rybelsus

For most of the GLP-1 era, taking one of these drugs meant a weekly injection. That changed quickly. Rybelsus arrived for type 2 diabetes, the Wegovy pill was approved for weight management in December 2025, and Foundayo (orforglipron) followed in April 2026. There are now three FDA-approved GLP-1 pills, and they differ in ways that matter.

The Comparison at a Glance

The Peptide Problem — and Why One Pill Escapes It

Two of these three pills contain semaglutide, a peptide. Peptides are chains of amino acids, and the digestive system is very good at breaking those down. Delivering one orally requires an absorption enhancer — in this case SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) — plus an empty stomach so the drug is not competing with food for absorption across the gastric mucosa.

That is the origin of the protocol both semaglutide pills share: take first thing in the morning, on an empty stomach, with no more than four ounces of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medications. Deviating from it does not just reduce comfort — it reduces absorption, and therefore efficacy.

Orforglipron sidesteps the problem entirely because it is a non-peptide small molecule. It binds the same GLP-1 receptor but is chemically robust enough to survive digestion unaided. No enhancer, no fasting window, no water ceiling, no timing rule.

Foundayo (Orforglipron)

Approved: April 1, 2026, for chronic weight management alongside a reduced-calorie diet and increased physical activity.

In Phase 3 ATTAIN-1, mean weight loss at 72 weeks reached 7.8%, 9.3%, and 12.4% across three dose levels versus 0.9% on placebo. At the highest dose, 54.6% of patients lost at least 10% of body weight and 36.0% lost at least 15%. Titration begins at 0.8 mg daily and steps monthly through 2.5, 5.5, 9, 14.5, and 17.2 mg, with color-coded tablets.

Strengths: No administration rules; lowest entry price of the three; not dependent on peptide manufacturing capacity. Limitations: Lowest efficacy of the weight-management options; no cardiovascular outcomes data; no diabetes indication yet; limited post-marketing history. Our full Foundayo review covers the evidence in depth.

Wegovy Pill (Oral Semaglutide 25 mg)

Approved: December 2025, for chronic weight management and for cardiovascular risk reduction in adults with obesity or overweight and established heart disease.

The OASIS 4 trial reported 16.6% mean weight loss over 64 weeks, with roughly one in three participants achieving at least 20% — efficacy comparable to injectable Wegovy 2.4 mg. Dosing escalates from 1.5 mg through 4 mg and 9 mg to a 25 mg maintenance dose.

Strengths: Highest efficacy among the pills; carries a cardiovascular indication; backed by the large semaglutide evidence base. Limitations: Strict daily fasting protocol; higher cost.

Rybelsus (Oral Semaglutide 7 mg / 14 mg)

Approved for type 2 diabetes, not weight management. Rybelsus is the original oral semaglutide, dosed lower than the Wegovy pill and indicated for glycemic control. Patients do lose some weight on it, but it was neither designed nor approved as an obesity therapy, and prescribing it for that purpose is off-label.

It shares the same fasting protocol as the Wegovy pill. For a patient with type 2 diabetes who wants an oral GLP-1, Rybelsus is the on-label choice; for weight management specifically, the other two are the appropriate comparators.

How Pills Compare to Injections

None of the oral options match injectable tirzepatide (Zepbound), which produces mean weight loss above 20% in its pivotal trials. The oral route buys convenience, not superior efficacy. The honest hierarchy on weight reduction alone runs: tirzepatide, then oral semaglutide 25 mg, then injectable semaglutide, then orforglipron.

That said, injections carry their own burdens — weekly self-administration, refrigerated storage, injection site rotation, and travel logistics. See injection site guidance and traveling with GLP-1 medications for what that actually involves day to day.

Choosing an Oral GLP-1

• Maximum weight loss from a pill: Wegovy pill, if the fasting protocol is realistic for you
• Established cardiovascular disease: Wegovy pill, which holds the CV indication
• Cannot or will not fast daily: Foundayo
• Cost-sensitive and paying cash: Foundayo at the lower doses
• Type 2 diabetes, oral preference: Rybelsus
• Medicare Part D: check the Foundayo $50/month rate available from July 2026

The Bottom Line

Three GLP-1 pills now exist, and they are not interchangeable. Rybelsus is a diabetes drug. The Wegovy pill is the efficacy leader among orals but carries a demanding daily protocol. Foundayo trades some efficacy for the removal of every administration constraint and the lowest entry price in the category.

The most common mistake is choosing on headline efficacy alone. A pill only works if it is taken as directed, and the protocol differences here are large enough to reverse the ranking for a substantial number of patients. Discuss the trade-off honestly with a prescriber who knows your routine.